| Autor: |
Rana, Ruhi, Kaur, Gagandeep, Kaur, Sukhanpreet, Kumar, Bimlesh, Melkani, Indu, Joshi, Kardam, Patel, Dhara, Porwal, Omji |
| Předmět: |
|
| Zdroj: |
AIP Conference Proceedings; 2024, Vol. 2986 Issue 1, p1-9, 9p |
| Abstrakt: |
Sildenafil (SD) is a well-known PDE5 selective inhibitor and reported to treat erectile dysfunction pulmonary hypertension, loss of memory neurological deficits and counter agent of neurogenesis targets. Phosphodiesterase 5 (PDE5) is one of eleven members of the mammalian phosphodiesterase family that hydrolyzes cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP). Rationale: A few years ago, sildenafil was approved for the treatment of pulmonary hypertension, thus renewing interest in cardiovascular applications, and tadalafil became available in once-daily formulations for erectile dysfunction management. Given the wide distribution of phosphodiesterase-5 throughout the body and its involvement in multiple functions, what can one expect in the future? To answer this we reviewed studies involving PDE-5 inhibitors that were published within the past three years and searched the US National Institutes of Health clinical trial registry for ongoing ones. Search of article were performed using PubMed, springer, google scholar, science direct, Bentham science, wiley, etc. IThis review mainly focuses on Phosphodietrase enzyme-types, location, and roles. Although researchers have proposed various pharmacological applications of sildenafil. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
